Exodus Point Capital Management, LP Checkpoint Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$0.97 - $1.77 $26,718 - $48,754	-27,545 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.53 - $3.25 $2,780 - $5,905	1,817 Added 7.06%	27,545 $49,000
Q4 2021 Feb 11, 2022	BUY	$2.68 - $4.46 $22,378 - $37,241	8,350 Added 48.05%	25,728 $80,000
Q3 2021 Nov 15, 2021	SELL	$2.5 - $3.53 $78,165 - $110,368	-31,266 Reduced 64.28%	17,378 $57,000
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $82,637 - $112,051	35,016 Added 256.94%	48,644 $143,000
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $35,432 - $56,692	13,628 New	13,628 $43,000
Q2 2020 Aug 14, 2020	SELL	$1.19 - $2.27 $16,239 - $30,978	-13,647 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.11 - $2.43 $15,148 - $33,162	13,647 New	13,647 $21,000
Q2 2019 Aug 14, 2019	SELL	$2.75 - $5.0 $97,413 - $177,115	-35,423 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.01 - $4.01 $71,200 - $142,046	35,423 New	35,423 $101,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $304M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.